INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
|
| Operating expenses: | ||
| Research and development, net | $ 2,924 | $ 2,616 |
| General and administrative | 2,227 | 2,859 |
| Operating loss | (5,151) | (5,475) |
| Financial income, net | 92 | 115 |
| Net loss | $ (5,059) | $ (5,360) |
| Basic net loss per share from continuing operations | $ (0.14) | $ (0.15) |
| Diluted net loss per share from continuing operations | $ (0.14) | $ (0.15) |
| Weighted average number of shares outstanding used in computing basic net loss per share | 36,735,435 | 36,436,882 |
| Weighted average number of shares outstanding used in computing diluted net loss per share | 36,735,435 | 36,436,882 |